BRAF-Mutant Melanoma Before a Wedding: Speed Against Durability in Treatment Sequencing
A single patient with a real, fixed date on the calendar and a hepatic tumor burden growing faster than that date allows for. The disagreement isn't about which drug works better in general — a randomized trial has already answered that — it's about whether this particular six-week window changes the answer.
R.O., a 46-year-old woman, is planning her son's wedding in six weeks and has spent the last several evenings finishing centerpieces at her kitchen table rather than resting, which is part of why she waited two extra weeks before mentioning the right-upper-quadrant discomfort and early satiety to anyone. A CT ordered for the symptoms found a 5.2cm hepatic metastasis and several smaller satellite lesions; biopsy confirmed BRAF V600E-mutant melanoma, metastatic from a thin primary excised from her calf four years ago that she'd been told was cured. Her AST and ALT are mildly elevated at roughly 1.5 times normal, consistent with a large lesion beginning to compress adjacent liver tissue rather than frank hepatic failure.
The sequencing question this case actually turns on was settled, at the population level, by DREAMseq: patients randomized to ipilimumab-nivolumab first, with BRAF/MEK inhibition held in reserve for progression, had a two-year overall survival of 72 percent, against 52 percent for the reverse order. That gap held even among patients with elevated LDH and higher disease burden — categories she partly meets. What DREAMseq's headline number doesn't capture is response speed: BRAF/MEK inhibitor combinations produce objective responses within one to two weeks in the large majority of patients, while checkpoint inhibition typically takes six to twelve weeks to show comparable shrinkage, an interval that overlaps almost exactly with the six weeks she has before walking her son down the aisle.
Her hepatic function bears directly on how much that gap actually matters clinically, not just symbolically. A hepatic lesion large enough to already be nudging her liver enzymes upward is a lesion with real room to keep growing before any systemic therapy takes effect — and unlike a soft-tissue or nodal metastasis, progressive hepatic replacement can move from mild enzyme elevation to synthetic dysfunction over a matter of weeks, not months, if the tumor outpaces treatment. Her albumin and INR remain normal today, which is the actual distinction between strained and failing liver function, and the number the team keeps returning to as the real early-warning signal to watch rather than the enzymes alone.
She has asked, more than once in this visit, whether there is a way to have both the wedding and the best odds — a question that has no clean answer but has genuinely shaped how the team is willing to think about sequencing rather than simply reciting DREAMseq's own top-line result back to her.
Deciding what six weeks is actually worth
DREAMseq answered this question directly: immunotherapy first, BRAF/MEK inhibition held in reserve. Two-year overall survival was 72 percent against 52 percent for the reverse sequence, and that advantage held across the elevated-LDH and higher-burden subgroups she partly falls into. I don't think a six-week personal deadline is a reason to override a randomized survival result we don't have an equivalent trial contradicting.
If her hepatic lesion were causing frank synthetic dysfunction rather than mild enzyme elevation, I'd take the urgency argument far more seriously. Right now her liver is under strain, not failing.
I'm not asking you to ignore DREAMseq. I'm asking whether its two-year survival curve is the only outcome that matters to her right now. She has a 5.2cm hepatic lesion already nudging her enzymes upward, and BRAF/MEK inhibition produces a response within one to two weeks in most patients against the six-to-twelve-week lag typical of checkpoint blockade. That gap sits almost exactly on top of the six weeks she has before her son's wedding — and if that lesion keeps growing during those weeks instead of shrinking, we may be trading a slightly better two-year curve for a genuinely worse six-week one.
You're right that her bilirubin is still normal and this isn't liver failure today. But 'not yet' isn't the same as 'won't be,' and a treatment that visibly shrinks disease within days is a real, different kind of answer for a patient whose actual near-term goal is walking, standing, and being present at one specific event.
Both of you are arguing about which outcome matters more, and I think DREAMseq's own crossover data actually answers the practical question underneath that argument. Patients assigned to BRAF/MEK-first were supposed to switch to immunotherapy at progression — and a real fraction never made that switch, because they progressed too fast or declined too much to tolerate it. 'Buy time now, switch later' sounds clean in a sentence and is harder to execute than that sentence suggests.
Given that, I'd start dabrafenib-trametinib now, get her through the response window and the wedding, and lock in an explicit switch date at week eight to ipilimumab-nivolumab regardless of how she's doing symptomatically — not contingent on progression being visible on a scan first, since waiting for radiographic progression is exactly what erodes the crossover rate in the trial data. That converts an open-ended 'switch later' into a fixed commitment neither side has to re-litigate under pressure.
Agreed: start dabrafenib-trametinib now, with a fixed, calendar-based switch to ipilimumab-nivolumab at week eight regardless of interval imaging findings.
Not fully agreed: the Medical Oncologist would prefer the switch decision remain contingent on an interval scan at week six rather than a fixed date, worried that a poor early response to the targeted combination might argue for switching sooner; the Clinical Pharmacologist held that any contingency reopens exactly the crossover-attrition risk the fixed date was designed to close. The fixed date carried the day for this plan, with an explicit agreement to revisit only if she develops new symptoms, not simply a less dramatic scan than hoped.